1. Generics Bulletin
  3. >>Value Added Medicines

Teva-MedinCell Alliance Heats Up With Second Phase III Trial Underway

Studies Begin For Proposed First Subcutaneous LAI Formulation Of Olanzapine

 
• By Dean Rudge

Teva’s partnership with MedinCell for long-acting injectable products, first penned a decade ago, is beginning to gather steam, as another candidate entered the clinic ahead of a potential first approval in the coming months.

3D illustration of files with schizophrenia diagnosis and treatment with antipsychotic medication and psychotherapy.
Invega and Risperdal Consta dominate the market • Source: Alamy

Teva is betting big on its partnership with MedinCell for long-acting injectables, recently describing the firms’ proposed 505(b)(2) hybrid risperidone LAI as a “gamechanger” for patients – while, as it awaits near-term regulatory action, also being a potential fillip for Teva’s spluttering margins.

Now MedinCell has announced that the pair’s second product candidate, the proposed first subcutaneous LAI formulation of olanzapine also for the treatment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Value Added Medicines

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

How To Make The Most Of Your GGB Awards Entries

 
• By Dave Wallace

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

Teva Shares Encouraging Patient Survey Data For Long-Acting Olanzapine

 
• By Adam Zamecnik

Doubling down on previously shared data from the firm’s STELARIS trial, Teva has reported further findings from a survey featuring subjects and professionals involved in the Phase III study for its proposed long-acting olanzapine injectable.

More from Products